These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 32726934)

  • 1. The Potential of Immune Modulation in Therapeutic HIV-1 Vaccination.
    Seddiki N; Picard F; Dupaty L; Lévy Y; Godot V
    Vaccines (Basel); 2020 Jul; 8(3):. PubMed ID: 32726934
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic HIV-1 vaccine: time for immunomodulation and combinatorial strategies.
    Seddiki N; Lévy Y
    Curr Opin HIV AIDS; 2018 Mar; 13(2):119-127. PubMed ID: 29329113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulatory T cells (Tregs): A major immune checkpoint to consider in combinatorial therapeutic HIV-1 vaccines.
    Hubert A; Seddiki N
    Hum Vaccin Immunother; 2018 Jun; 14(6):1432-1437. PubMed ID: 29381418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic vaccines and immunological intervention in HIV infection: a paradigm change.
    Pantaleo G; Levy Y
    Curr Opin HIV AIDS; 2016 Nov; 11(6):576-584. PubMed ID: 27607591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV-1 Reservoir Dynamics after Vaccination and Antiretroviral Therapy Interruption Are Associated with Dendritic Cell Vaccine-Induced T Cell Responses.
    Andrés C; Plana M; Guardo AC; Alvarez-Fernández C; Climent N; Gallart T; León A; Clotet B; Autran B; Chomont N; Gatell JM; Sánchez-Palomino S; García F
    J Virol; 2015 Sep; 89(18):9189-99. PubMed ID: 26109727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic conserved elements (CE) DNA vaccine induces strong T-cell responses against highly conserved viral sequences during simian-human immunodeficiency virus infection.
    Munson P; Liu Y; Bratt D; Fuller JT; Hu X; Pavlakis GN; Felber BK; Mullins JI; Fuller DH
    Hum Vaccin Immunother; 2018 Jul; 14(7):1820-1831. PubMed ID: 29648490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Developing Combined HIV Vaccine Strategies for a Functional Cure.
    Noto A; Trautmann L
    Vaccines (Basel); 2013 Oct; 1(4):481-96. PubMed ID: 26344343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene Expression Signatures Associated With Immune and Virological Responses to Therapeutic Vaccination With Dendritic Cells in HIV-Infected Individuals.
    Thiébaut R; Hejblum BP; Hocini H; Bonnabau H; Skinner J; Montes M; Lacabaratz C; Richert L; Palucka K; Banchereau J; Lévy Y
    Front Immunol; 2019; 10():874. PubMed ID: 31105698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short communication: HIV antigen-specific reactivation of HIV infection from cellular reservoirs: implications in the settings of therapeutic vaccinations.
    Shete A; Thakar M; Singh DP; Gangakhedkar R; Gaikwad A; Pawar J; Paranjape R
    AIDS Res Hum Retroviruses; 2012 Aug; 28(8):835-43. PubMed ID: 21936714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of virus replication after vaccination of HIV-1-infected individuals.
    Staprans SI; Hamilton BL; Follansbee SE; Elbeik T; Barbosa P; Grant RM; Feinberg MB
    J Exp Med; 1995 Dec; 182(6):1727-37. PubMed ID: 7500017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Understanding HIV infection for the design of a therapeutic vaccine. Part II: Vaccination strategies for HIV.
    de Goede AL; Vulto AG; Osterhaus AD; Gruters RA
    Ann Pharm Fr; 2015 May; 73(3):169-79. PubMed ID: 25528627
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Toll-Like Receptor 7 Agonist GS-9620 Induces HIV Expression and HIV-Specific Immunity in Cells from HIV-Infected Individuals on Suppressive Antiretroviral Therapy.
    Tsai A; Irrinki A; Kaur J; Cihlar T; Kukolj G; Sloan DD; Murry JP
    J Virol; 2017 Apr; 91(8):. PubMed ID: 28179531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV-1 T cell epitopes targeted to Rhesus macaque CD40 and DCIR: A comparative study of prototype dendritic cell targeting therapeutic vaccine candidates.
    Flamar AL; Bonnabau H; Zurawski S; Lacabaratz C; Montes M; Richert L; Wiedemann A; Galmin L; Weiss D; Cristillo A; Hudacik L; Salazar A; Peltekian C; Thiebaut R; Zurawski G; Levy Y
    PLoS One; 2018; 13(11):e0207794. PubMed ID: 30500852
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Priming with a Potent HIV-1 DNA Vaccine Frames the Quality of Immune Responses prior to a Poxvirus and Protein Boost.
    Asbach B; Kibler KV; Köstler J; Perdiguero B; Yates NL; Stanfield-Oakley S; Tomaras GD; Kao SF; Foulds KE; Roederer M; Seaman MS; Montefiori DC; Parks R; Ferrari G; Forthal DN; Phogat S; Tartaglia J; Barnett SW; Self SG; Gottardo R; Cristillo AD; Weiss DE; Galmin L; Ding S; Heeney JL; Esteban M; Jacobs BL; Pantaleo G; Wagner R
    J Virol; 2019 Feb; 93(3):. PubMed ID: 30429343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman Primates.
    García-Arriaza J; Perdiguero B; Heeney JL; Seaman MS; Montefiori DC; Yates NL; Tomaras GD; Ferrari G; Foulds KE; Roederer M; Self SG; Borate B; Gottardo R; Phogat S; Tartaglia J; Barnett SW; Burke B; Cristillo AD; Weiss DE; Lee C; Kibler KV; Jacobs BL; Wagner R; Ding S; Pantaleo G; Esteban M
    J Virol; 2017 May; 91(9):. PubMed ID: 28179536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [HIV/AIDS vaccines: heading for new vaccine approaches?].
    Girard MP
    Bull Soc Pathol Exot; 2008 Jun; 101(3):220-6. PubMed ID: 18681215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A therapeutic HIV-1 vaccine enhances anti-HIV-1 immune responses in patients under highly active antiretroviral therapy.
    Tung FY; Tung JK; Pallikkuth S; Pahwa S; Fischl MA
    Vaccine; 2016 Apr; 34(19):2225-32. PubMed ID: 27002500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. iHIVARNA phase IIa, a randomized, placebo-controlled, double-blinded trial to evaluate the safety and immunogenicity of iHIVARNA-01 in chronically HIV-infected patients under stable combined antiretroviral therapy.
    de Jong W; Aerts J; Allard S; Brander C; Buyze J; Florence E; van Gorp E; Vanham G; Leal L; Mothe B; Thielemans K; Plana M; Garcia F; Gruters R;
    Trials; 2019 Jun; 20(1):361. PubMed ID: 31208472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Understanding HIV infection for the design of a therapeutic vaccine. Part I: Epidemiology and pathogenesis of HIV infection.
    de Goede AL; Vulto AG; Osterhaus AD; Gruters RA
    Ann Pharm Fr; 2015 Mar; 73(2):87-99. PubMed ID: 25496723
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rationale for an Association Between PD1 Checkpoint Inhibition and Therapeutic Vaccination Against HIV.
    Filaci G; Fenoglio D; Taramasso L; Indiveri F; Di Biagio A
    Front Immunol; 2018; 9():2447. PubMed ID: 30459765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.